See more : Eon Electric Limited (EON.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Nabriva Therapeutics plc (NBRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nabriva Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Gelion plc (GELN.L) Income Statement Analysis – Financial Results
- Sats ASA (SATS.OL) Income Statement Analysis – Financial Results
- Cromwell European Real Estate Investment Trust (CWBU.SI) Income Statement Analysis – Financial Results
- Secured Services, Inc. (SSVC) Income Statement Analysis – Financial Results
- First Merchants Corporation (FRME) Income Statement Analysis – Financial Results
Nabriva Therapeutics plc (NBRV)
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.67M | 27.22M | 2.86M | 7.75M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Cost of Revenue | 28.58M | 13.15M | 766.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.09M | 14.07M | 2.10M | 7.68M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.87% | 51.69% | 73.25% | 99.10% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 14.26M | 12.63M | 15.10M | 26.42M | 82.29M | 49.62M | 47.99M | 22.73M | 8.59M | 10.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.26M | 51.65M | 55.29M | 62.49M | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Other Expenses | -1.27M | -1.68M | -2.16M | -1.73M | -272.00K | 492.00K | 55.00K | 2.86M | 77.82K | 34.30M |
| Operating Expenses | 58.26M | 62.60M | 68.22M | 87.17M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Cost & Expenses | 86.84M | 75.74M | 68.99M | 87.24M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Interest Income | 0.00 | 0.00 | 86.00K | 255.00K | 49.00K | 318.00K | 343.00K | 6.74M | 2.43K | 307.93K |
| Interest Expense | 698.00K | 0.00 | 1.74M | 3.64M | 133.00K | 43.00K | 75.00K | 14.59M | 6.98M | 5.55M |
| Depreciation & Amortization | -3.53M | 637.00K | 1.27M | 470.00K | 510.00K | 432.00K | 233.00K | 150.88K | 152.00K | 197.46K |
| EBITDA | -54.70M | -48.53M | -64.85M | -79.02M | -114.09M | -72.53M | -54.42M | -17.24M | -9.75M | 28.06M |
| EBITDA Ratio | -153.36% | -178.31% | -2,264.42% | -1,019.86% | -1,755.20% | 0.00% | 0.00% | -20,518.94% | 0.00% | 0.00% |
| Operating Income | -51.17M | -48.53M | -66.13M | -79.49M | -114.38M | -73.77M | -55.05M | -23.98M | -9.77M | 22.31M |
| Operating Income Ratio | -143.47% | -178.31% | -2,308.87% | -1,025.93% | -1,759.62% | 0.00% | 0.00% | -28,544.30% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | -432.00K | -3.22M | -3.17M | -356.00K | 767.00K | -515.00K | 2.86M | -6.42M | -5.76M |
| Income Before Tax | -55.62M | -48.96M | -69.35M | -82.66M | -114.73M | -73.00M | -55.56M | -31.82M | -16.18M | 16.55M |
| Income Before Tax Ratio | -155.93% | -179.89% | -2,421.26% | -1,066.89% | -1,765.09% | 0.00% | 0.00% | -37,886.83% | 0.00% | 0.00% |
| Income Tax Expense | 1.57M | 490.00K | 139.00K | 101.00K | 49.00K | 1.36M | -672.00K | -438.41K | 87.55K | 1.07M |
| Net Income | -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | -74.36M | -54.89M | -31.39M | -16.27M | 15.48M |
| Net Income Ratio | -160.33% | -181.69% | -2,426.12% | -1,068.20% | -1,765.85% | 0.00% | 0.00% | -37,364.91% | 0.00% | 0.00% |
| EPS | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 142.25 |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 130.92 |
| Weighted Avg Shares Out | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
| Weighted Avg Shares Out (Dil) | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
Nabriva Announces Changes to its Board of Directors
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Nabriva Therapeutics Stock Is Surging Today
NBRV Stock Price: Over 60% Increase Pre-Market Explanation
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
Source: https://incomestatements.info
Category: Stock Reports